Effects of cabergoline and dimethylcabergoline on the sexual behavior of male rats. Psychopharmacology

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F24%3A43921189" target="_blank" >RIV/00023752:_____/24:43921189 - isvavai.cz</a>

Výsledek na webu

<a href="https://link.springer.com/article/10.1007/s00213-023-06501-9" target="_blank" >https://link.springer.com/article/10.1007/s00213-023-06501-9</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00213-023-06501-9" target="_blank" >10.1007/s00213-023-06501-9</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Effects of cabergoline and dimethylcabergoline on the sexual behavior of male rats. Psychopharmacology

Popis výsledku v původním jazyce

Rationale Cabergoline (CAB) is an ergot derivative typically prescribed for the treatment of hyperprolactinemia. It suppressesthe release of prolactin through agonist actions on dopamine (DA) D2 receptors; however, it possesses binding afnity forother DA and 5-HT receptors. Side efects that exacerbate valvular heart disease can occur with high doses.Objective The present study examined the acute, subchronic, and chronic dose–response efects of CAB and a derivativedimethylcabergoline (DMC) which acts as an antagonist instead of agonist at 5-HT 2B receptors, on appetitive and consummatory sexual behaviors of male rats.Methods CAB (0, 0.03, 0.15, or 0.3 mg/kg/ml) was administered daily to sexually experienced male rats (N=10/dose) byoral gavage for a total of 68 days. Sexual behavior was tested every 4 days during this period for a total of 16 trials. On the17th trial, rats were administered their dose of CAB, and 4 h after were overdosed with sodium pentobarbital, perfused intracardially, and their brains processed for Fos immunohistochemistry. DMC (0, 0.03, 0.15, 0.3 mg/kg/ml) was administereddaily to sexually experienced male rats (N=10/dose) by oral gavage for a total of 36 days. Sexual behavior was tested every4 days for a total of 9 trials.Results CAB increased anticipatory level changes, intromissions, and ejaculations signifcantly across all timepoints, withthe medium and high doses being most potent. The medium and high doses also increased Fos protein signifcantly withinthe medial preoptic area, whereas in the nucleus accumbens shell, the low and medium doses decreased Fos protein but thehigh dose increased it signifcantly from control. Similar to CAB, the medium and high doses of DMC increased the numberof ejaculations signifcantly. Rats in all drug dose groups appeared healthy for the duration of the experiments.Conclusions Both CAB and DMC facilitate ejaculations, and CAB further facilitates measures of anticipatory sexual motivation and intromissions. These data suggest that both could be used as treatments for sexual arousal disorders and ejaculation/orgasm disorders with little or no untoward side efects at low doses.

Název v anglickém jazyce

Effects of cabergoline and dimethylcabergoline on the sexual behavior of male rats. Psychopharmacology

Popis výsledku anglicky

Rationale Cabergoline (CAB) is an ergot derivative typically prescribed for the treatment of hyperprolactinemia. It suppressesthe release of prolactin through agonist actions on dopamine (DA) D2 receptors; however, it possesses binding afnity forother DA and 5-HT receptors. Side efects that exacerbate valvular heart disease can occur with high doses.Objective The present study examined the acute, subchronic, and chronic dose–response efects of CAB and a derivativedimethylcabergoline (DMC) which acts as an antagonist instead of agonist at 5-HT 2B receptors, on appetitive and consummatory sexual behaviors of male rats.Methods CAB (0, 0.03, 0.15, or 0.3 mg/kg/ml) was administered daily to sexually experienced male rats (N=10/dose) byoral gavage for a total of 68 days. Sexual behavior was tested every 4 days during this period for a total of 16 trials. On the17th trial, rats were administered their dose of CAB, and 4 h after were overdosed with sodium pentobarbital, perfused intracardially, and their brains processed for Fos immunohistochemistry. DMC (0, 0.03, 0.15, 0.3 mg/kg/ml) was administereddaily to sexually experienced male rats (N=10/dose) by oral gavage for a total of 36 days. Sexual behavior was tested every4 days for a total of 9 trials.Results CAB increased anticipatory level changes, intromissions, and ejaculations signifcantly across all timepoints, withthe medium and high doses being most potent. The medium and high doses also increased Fos protein signifcantly withinthe medial preoptic area, whereas in the nucleus accumbens shell, the low and medium doses decreased Fos protein but thehigh dose increased it signifcantly from control. Similar to CAB, the medium and high doses of DMC increased the numberof ejaculations signifcantly. Rats in all drug dose groups appeared healthy for the duration of the experiments.Conclusions Both CAB and DMC facilitate ejaculations, and CAB further facilitates measures of anticipatory sexual motivation and intromissions. These data suggest that both could be used as treatments for sexual arousal disorders and ejaculation/orgasm disorders with little or no untoward side efects at low doses.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30105 - Physiology (including cytology)

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Psychopharmacology

ISSN

0033-3158

e-ISSN

1432-2072

Svazek periodika

241

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

10

Strana od-do

717-726

Kód UT WoS článku

001102302300002

EID výsledku v databázi Scopus

2-s2.0-85176813368